Potential Function of Amniotic Fluid in Fetal Development—Novel Insights by Comparing the Composition of Human Amniotic Fluid with Umbilical Cord and Maternal Serum at Mid and Late Gestation  by Tong, Xing-Long et al.
J Chin Med Assoc • July 2009 • Vol 72 • No 7368
© 2009 Elsevier. All rights reserved.
Introduction
Amniotic fluid (AF), the protecting liquid contained
in the amnion cavity, is an essential component for fetal
development and maturation during pregnancy. In early
embryogenesis, AF is the extension of the fetal extra-
cellular matrix and free diffusion occurs bidirectionally
between the fetus and the AF through extracellular
compartment. By 8 weeks of gestation in humans, the
urethra is formed and the fetal kidneys start to produce
urine. Fetal swallowing begins shortly thereafter. Fetal
skin is gradually keratinized from 19 to 25 weeks of ges-
tation. Excretion from fetal urine, respiratory system,
gastroenteric system, umbilical cord and surface of
the placenta become the sources of AF.1
It is well accepted that AF constitutes a protective
sac around the fetus that allows fetal movement and
growth and prevents mechanical and thermal shock.
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It also plays a significant defensive role as a part of the
innate immune system since AF has an organized pool
of antimicrobial peptides against common bacterial and
fungal pathogens.2 AF is 98% water and electrolytes,
proteins, peptides, carbohydrates, lipids and hormones.
The levels of these components in AF have been deter-
mined in many studies to screen for potential biomark-
ers of pregnancy-associated abnormalities. In recent
years, an increasing number of proteins or peptides
have been isolated from AF. Among these proteins,
more and more are identified as growth factors or
cytokines,3–5 the levels of which usually change as
gestation advances and they also demonstrate a differ-
ent dynamic pattern from the maternal plasma.4,6,7
Our previous study has shown that proteins in human
AF from specific gestational age inhibit tumor growth
in tumor-bearing mice.8 In addition, AF has attracted
increasing attention in recent years as a possible reserve
of stem cells.9 The above evidence suggests that the
bioactive components in AF may play an important
role in fetal development and maturation. However,
up to now, little is known about the physiological
functions of the majority of the constituents of AF.
We suppose that AF may play a pivotal role in fetal
development in addition to its protective effect on the
fetus. The aim of this study was to provide new evi-
dence to support our assumption by comparing the
composition of human AF with corresponding umbil-
ical cord serum (UCS) and maternal serum (MS) at
mid and late gestation.
Methods
Collection of AF, UCS and MS
Forty-six healthy pregnant women aged 22–37 years
undergoing legal pregnancy terminations or normal
labor were enrolled in this study. They all signed an
informed consent form. The mean gestational age was
27 weeks (range, 15–42 weeks). AF samples were ob-
tained transcervically or from the uterus during deliv-
ery by elective cesarean section. Umbilical cord blood
was drawn from the middle part of the umbilical cord.
Maternal blood was obtained from median cubital veins.
From each pregnant woman, AF, umbilical cord blood
and maternal blood were simultaneously collected.
Serums were prepared according to routine procedure.
AF samples were first filtered and then cleared of cells
by centrifuge (3000 rpm/min for 10 minutes at 4°C),
frozen, and stored in aliquots at −20°C. Exclusion cri-
teria included: multiple pregnancies, diabetes, infection,
fetal malformation, gestational hypertension, hepatitis
B or C antigen positive, maternal exposure to alcohol,
cocaine or tobacco smoke. The study protocol was ap-
proved by the ethics committee of the local hospital.
Measurement of biochemical components
A total of 38 biochemical components and osmolality
were simultaneously quantified in the AF, UCS, and
MS samples from each pregnant woman using an
automatic biochemical analyzer (Olympus AU5400;
Olympus Corp., Tokyo, Japan) with assay kits. The bio-
chemical components included total protein, albumin,
globulin, alanine aminotransferase, aspartate amino-
transferase, alkaline phosphatase, γ-transpeptidase, cho-
linesterase, creatine kinase, creatine kinase isoenzymes,
lactate dehydrogenase, hydroxybutyrate dehydrogenase,
amylase, glucose, cholesterol, triglyceride, high-density
lipoprotein (HDL), low-density lipoprotein (LDL),
very-low-density lipoprotein (VLDL), apoprotein A1
and B, lipoprotein(a), total bilirubin, direct bilirubin,
indirect bilirubin, total bile, sodium, potassium, chlo-
ride, calcium, phosphate, magnesium, bicarbonate,
urea, creatinine, anion gap, uric acid, and osmolality.
Measurement of tumor markers
Levels of tumor markers including α-fetoprotein (AFP),
carcinoembryonic antigen (CEA), ferritin, cancer anti-
gen 125 (CA-125) and 199 (CA-199) were measured
in the AF, UCS and MS from each pregnant woman
with the UniCelTM DxI 800 Access Immunoassay
System (Beckman Coulter Inc., Fullerton, CA, USA).
For each gestational age in the range of 15–42 weeks,
2 pregnancies were subjected to the test.
Statistical analysis
The data are presented as mean ± standard deviation.
Statistical comparisons between AF and UCS or MS
were carried out using GraphPad InStat version 3
(GraphPad Software Inc., La Jolla, CA, USA) with
Student’s paired t tests. A value of p < 0.05 was con-
sidered statistically significant.
Results
Biochemical components in AF, UCS and MS
Thirty-eight components including proteins, elec-
trolytes, glucose, triglyceride and metabolites were
simultaneously determined in the AF, UCS and MS
samples from each pregnant woman. Matched sam-
ples were from 20 subjects. As shown in Table 1, pro-
teins including total protein, albumin, globulin, and
various enzymes were present in significantly lower
concentrations in AF than in UCS or MS. The mean
concentration of total protein in the matched samples
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was 8 times higher in UCS and 12.5 times higher in
MS than in AF. As shown in Table 2, the concentration
of the dominant cation, sodium, in AF was the same
as in UCS, but slightly lower than in MS. Other
minor cations, including potassium, calcium and mag-
nesium, were present in lower concentrations in AF
than in UCS and MS. No difference was found for
the levels of the primary anion, chloride, and anion
gap between AF and UCS or MS. There was a much
lower level of glucose in AF than in UCS or MS.
Triglyceride and cholesterol were almost undetectable.
The levels of total bilirubin and bile acid were much
lower in AF than in UCS and MS. However, some
metabolites including urea, creatinine, and uric acid
occurred at higher concentrations in AF than in UCS
or MS. The osmolality of AF was the same as that of
UCS, but slightly lower than that of MS.
Levels of tumor markers
The levels of tumor markers including CEA, ferritin,
CA-125, CA-199 and AFP were quantified at the dif-
ferent gestational ages and shown in Figure 1. The con-
centrations of these proteins in AF displayed dynamic
changes as gestation advanced. Compared to UCS and
MS, AF showed a different dynamic pattern of tumor
markers at mid and late gestation.
Discussion
There are few reports on the comparison of composi-
tions among AF, UCS and MS since it is difficult to
obtain human AF, UCS and MS samples at mid and
late gestation from the same subject. By comparing
the biochemical components, electrolytes and tumor-
related proteins in human AF, UCS and MS, we
found that: (1) the levels of primary electrolytes such
as sodium, chloride, anion gap and osmotic pressure
in AF were almost the same as in UCS and MS; (2)
the levels of organic substances in AF, including total
protein, glucose, triglyceride, cholesterol and various
enzymes, were markedly lower than in UCS and MS,
especially total protein, which was 8- and 12.5-fold
lower in AF compared to UCS and MS, respectively;
(3) the levels of tumor markers, including CEA, fer-
ritin, CA-125, CA-199 and AFP, in AF displayed dif-
ferent dynamic changes from that in UCS and MS as
gestation advanced. These data suggest that the inor-
ganic components in AF may be derived from blood,
but other organic components such as protein, enzymes
and tumor markers are present in AF at significantly
different levels than in UCS and MS. The results imply
that the fetus is the main source of these components
in AF and that AF is an independent fluid.
Table 1. Levels of proteins in amniotic fluid (AF), umbilical cord serum (UCS) and maternal serum (MS) at mid and late gestation in 
20 subjects*
Biochemical components AF UCS MS
Total protein (g/L) 4.87 ± 2.08†‡ 39.46 ± 9.12 61.55 ± 6.36
Albumin (g/L) 2.24 ± 1.39†‡ 27.35 ± 4.99 35.06 ± 4.39
Globulin (g/L) 2.63 ± 0.74†‡ 12.11 ± 4.97 26.84 ± 3.58
ALT (U/L) 0.80 ± 0.70†‡ 4.50 ± 2.65 6.25 ± 2.49
AST (U/L) 8.40 ± 4.28†‡ 34.50 ± 15.36 17.95 ± 5.12
Alk-P (U/L) 19.80 ± 18.14†‡ 161.10 ± 65.15 82.65 ± 49.08
Cholinesterase (U/L × 103) 0.04 ± 0.06†‡ 4.49 ± 1.31 5.58 ± 0.98
γ-transpeptidase (U/L) 148.30 ± 179.01†‡ 123.25 ± 61.47 17.10 ± 20.56
CK (U/L) 1.00 ± 1.21†‡ 171.25 ± 125.75 70.75 ± 70.16
CK isoenzymes (U/L) 2.75 ± 2.77†‡ 71.35 ± 83.55 14.90 ± 7.00
LDH (U/L) 17.60 ± 18.02†‡ 376.75 ± 173.40 208.65 ± 64.03
Hydroxybutyrate dehydrogenase (U/L) 14.90 ± 14.46†‡ 296.75 ± 141.16 169.40 ± 53.45
Amylase (U/L) 74.20 ± 16.26† 48.40 ± 18.15 82.80 ± 14.92
HDL (mmol/L) 0.016 ± 0.015†‡ 0.645 ± 0.20 1.71 ± 0.47
LDL (mmol/L) 0.32 ± 0.02†‡ 1.18 ± 0.50 2.58 ± 0.98
VLDL (mmol/L) 0.001 ± 0.003†‡ 0.21 ± 0.20 1.20 ± 0.76
Apoprotein A1 (g/L) 0.012 ± 0.013†‡ 0.59 ± 0.18 2.02 ± 0.52
Apoprotein B (g/L) 0.120 ± 0.002†‡ 0.31 ± 0.086 0.93 ± 0.27
Lipoprotein(a) (mg/L) 84.53 ± 15.41‡ 86.03 ± 13.42 286.72 ± 229.86
*Data presented as mean ± standard deviation; †p < 0.01 vs. UCS; ‡p < 0.01 vs. MS. ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
Alk-P = alkaline phosphatase; CK = creatine kinase; LDH = lactate dehydrogenase; HDL = high-density lipoprotein; LDL = low-density lipoprotein; VLDL = very-low-
density lipoprotein.
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It is generally accepted that AF serves as an exten-
sion of the fetal extracellular matrix in early gestation.
After the fetal skin is fully keratinized, fetal respira-
tion, swallowing, and excretion of urine constitute
the main pathways of exchange between the fetus and
AF.1 Our study revealed that much higher concentra-
tions of metabolites including urea, creatinine, and uric
acid were found in AF, representing the excretion of
urine from the fetus. Compared to umbilical blood,
AF contained significantly fewer nutritional compo-
nents such as proteins, glucose, triglyceride and cho-
lesterol, which may suggest that AF does not have an
important role in fetal nutrition. What is the potential
function of AF in fetal development? In this study, the
mean total protein in human AF was 4.9 g/L at mid
and late gestation, which was significantly lower than in
UCS and MS; this finding is consistent with a previous
report.10 Since both electrolytes and proteins are key
factors in maintaining osmotic pressure, it is expected
that the proteins found in AF have low molecular
weights if a low level of total proteins in AF is required
to maintain the balance of osmotic pressure between AF
and blood. There is evidence that most of the proteins
or polypeptides in AF are of low molecular weight.11
Among these proteins or peptides, more and more
are being identified as tumor markers, growth factors
and cytokines, which possess potent bioactivity.3–5,12
A study has demonstrated that growth factors in AF
are able to be absorbed by the fetal gastrointestinal
tract and transported to the whole fetal body.13 Thus,
proteins in AF may play an important role in fetal devel-
opment. It has been demonstrated that AFP is capable
of regulating growth in ovarian, placental, uterine,
phagocytic, bone marrow and lymphatic cells.14,15 Our
previous study showed that proteins or peptides with
small molecular weight in human AF at specific gesta-
tional ages displayed opposite effects,8 i.e. suppression
or acceleration on mouse tumor growth. More recently,
AF composition at 19–20 weeks of gestation was deter-
mined by proteomics analysis and a total of 842 pro-
teins and peptides were identified, the functions of
which included cellular movement, development of
organs, cellular growth and proliferation.16 The above
data suggest that proteins or peptides in AF modulate
the process of fetal development in addition to its
protective effect. Together with other reports,8,16 we
hypothesize that these proteins act as regulatory mes-
sengers for cellular growth and proliferation and that
AF provides a pathway to transport these messengers
to the whole fetal body. In this way, AF plays a pivotal
role in fetal development.
In conclusion, the present study demonstrated
that AF is not a result of simple filtration from the
blood but an independent fluid. We speculate that
proteins or peptides in AF modulate the process of
fetus development since they possess potent bioactivity
Table 2. Levels of biochemical components in amniotic fluid (AF), umbilical cord serum (UCS) and maternal serum (MS) at mid and
late gestation in 20 subjects*
Biochemical components AF UCS MS
Total bilirubin (μmol/L) 2.23 ± 1.28†‡ 24.57 ± 8.04 8.10 ± 5.54
Direct bilirubin (μmol/L) 1.13 ± 0.66†‡ 8.06 ± 2.75 2.24 ± 1.36
Indirect bilirubin (μmol/L) 1.10 ± 0.73†‡ 16.52 ± 6.12 5.86 ± 4.32
Total bile acid (μmol/L) 1.48 ± 0.80†‡ 5.98 ± 2.34 2.30 ± 1.08
Sodium (mmol/L) 129.9 ± 11.65§ 133 ± 5.39 136 ± 2.06
Potassium (mmol/L) 3.80 ± 0.41†‡ 7.32 ± 2.48 5.94 ± 2.20
Chloride (mmol/L) 106.18 ± 7.82 103.03 ± 2.01 103.17 ± 2.27
Calcium (mmol/L) 1.42 ± 0.26†‡ 2.45 ± 0.16 2.22 ± 0.12
Phosphate (mmol/L) 1.12 ± 0.23†‡ 2.19 ± 0.59 1.53 ± 0.82
Magnesium (mmol/L) 0.59 ± 0.09†‡ 0.92 ± 0.19 0.85 ± 0.12
Bicarbonate (mmol/L) 14.00 ± 2.97†‡ 18 ± 3.76 17 ± 3.18
Glucose (mmol/L) 1.29 ± 0.72†‡ 3.45 ± 1.16 3.58 ± 1.79
Cholesterol (mmol/L) 0.04 ± 0.02†‡ 1.95 ± 0.61 5.37 ± 1.22
Triglyceride (mmol/L) 0.010 ± 0.007†‡ 0.47 ± 0.44 2.66 ± 1.67
Urea (mmol/L) 3.34 ± 0.94† 2.81 ± 0.57 3.07 ± 0.84
Creatinine (μmol/L) 100.15 ± 54.91†‡ 55 ± 9.95 57 ± 9.17
Anion gap (mmol/L) 9.75 ± 6.46 11.80 ± 6.45 15.60 ± 5.29
Uric acid (μmol/L) 289.40 ± 97.84†§ 238.5 ± 64.12 253.6 ± 67.49
Osmolality (mosm/L) 246.85 ± 21.51§ 254.2 ± 10.14 259.8 ± 3.74
*Data presented as mean ± standard deviation; †p < 0.01 vs. UCS; ‡p < 0.01 vs. MS; §p < 0.05 vs. MS.
J Chin Med Assoc • July 2009 • Vol 72 • No 7372
X.L. Tong, et al
on cellular growth and proliferation. AF provides a
pathway to transport these “regulatory messengers”
to the whole fetal body and thus plays a pivotal role 
in fetal development. To define this novel function of
AF would potentially be significant for better under-
standing of embryonic development, prevention of
genetic diseases and developing new therapeutics for
human malignancies.
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Figure 1. Dynamic changes of tumor markers in amniotic fluid
(white circle), umbilical cord serum (black circle) and maternal
serum (black triangle) with advancing gestation: (A) carcinoem-
bryonic antigen (CEA); (B) ferritin; (C) cancer antigen 125 (CA-
125); (D) cancer antigen 199 (CA-199); (E) α-fetoprotein (AFP).
Samples were obtained from 36 subjects; n = 2 for each week of
gestation.
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